Overview:

Conduct smarter oncology R&D faster with SpecimenSeq

Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. SpecimenSeq makes this challenge easier for targeted oncology developers by delivering access to fully consented, ethically collected DTCs and DTCs matched sets that are comprehensively annotated by genomic, phenotypic, and clinical characteristics.

Contact Our Biospecimens Team

SpecimenSeq™ Allows Companies to Accelerate:

Biomarker Discovery

Verification of the presence of biomarker targets in your populations of interest

Assessing Mutations

Confirmation of driver mutations and other clinically relevant genomic variants in viable DTCs

Oncology Therapeutics

Acceleration of timelines for identifying responders versus non-responders and efficacy evaluations for new cancer therapies

Deliverables & Characterization:

Standalone DTCs and DTCs Matched Sets
Biospecimen FormatCharacterization Reports
DTCs
  • Clinical information and pathology report
  • Cell population analysis and HLA-A02 status by flow cytometry
  • HAD QGEN MultiModal service with QCI report
DTCs + PBMCs
  • Clinical information and pathology report
  • Cell population analysis and HLA-A02 status by flow cytometry (DTCs only)
  • HAD QGEN MultiModal service with QCI report (DTCs only)
DTCs + FFPE
  • Clinical information and pathology report
  • Cell population analysis and HLA-A02 status by flow cytometry (DTCs only)
  • HAD QGEN MultiModal service with QCI report (DTCs only)
DTCs + PBMCs + FFPE
  • Clinical information and pathology report
  • Cell population analysis and HLA-A02 status by flow cytometry (DTCs only)
  • HAD QGEN MultiModal service with QCI report (DTCs only)
NGS Characterization
DNA Gene Content (64 genes)
ABL1CDH1ERFLT3IDH2MLH1PDGFRASMAD4
AKT1CDKN2AERBB2FOXL2JAK2MPLPIK3CASMARCB1
ALKCSF1RERBB4GNA11JAK3MSH2PMS2SMO
APCCTLA4EZH2GNAQKDRMSH6PRSRC
ATMCTNNB1FBXW7GNASKITMUM1PTENSTK11
BCL6DDR2FGFR1HNF1AKRASNOTCH1PTPN11TP53
BRAFDNMT3AFGFR2HRASMAP2K1NPM1RB1TSC1
CD10EGFRFGFR3IDH1METNRASRETVHL
RNA Gene Fusion Content (6 primary genes)
EML4-ALKMPRIP-NTRK1NCOA4-RET
GCC2-ALKSQSTM1-NTRK1TRIM33-RET
HIP1-ALKTPR-NTRK1CD74-ROS1
KIF5B-ALKTRIM24-NTRK2EZR-ROS1
KLC1-ALKETV6-NTRK3GOPC-ROS1
STRN-ALKSQSTM1-NTRK3LRIG3-ROS1
TFG-ALKCCDC6-RETSDC4-ROS1
TPR-ALKCUX1-RETSLC34A2-ROS1
CD74-NTRK1KIAA1217-RETTPM3-ROS1
IRF2BP2-NTRK1KIF5B-RET
NGS results are delivered via a Qiagen Clinical Insights (QCI) report that includes:
  • Genomic variants that have been shown to have clinical relevance
  • Pathogenicity and level of clinical significance according to clinical guidelines
  • Predicted protein changes
  • Relevant drug treatments or resistance to drugs based on the genetic variants
  • Relevant active clinical trials for patients that would harbor the same genomic variants as were identified in the biospecimen sample
Download a Sample Report
Additional characterizations are available through our expert, integrated service laboratories.
Cell Services
Learn More
IHC Services
Learn More

Submit Inventory Requests

Highlight your samples of interest and submit the saved inventory report file via the contact form below.